Google DeepMind
The company will use the funds for AI research and to advance its programs in clinical development.
AlphaProteo was created to advance drug design and disease understanding by helping researchers configure high-strength proteins that bind to molecules.
Tx-LLM was fine-tuned from Google's Med-PaLM 2 and created to analyze a variety of chemical or biological entities to assist with the drug-discovery pipeline.
Med-Gemini-3D can read 3D scans, generate radiology reports and answer questions, while Med-Gemini-Polygenic can predict health outcomes based on genomic data.
The tech giant revealed it created an LLM optimized for diagnostic reasoning with the ability to generate a differential diagnosis or assist clinicians in coming to a diagnosis.
The app was used by the U.K.’s National Health Service to help clinicians access patient information, but most NHS Trusts had reportedly stopped using it.
DeepMind's artificial intelligence system appears to diagnose eye disease as accurately as leading human specialists, according to new research published in the journal Nature Medicine.
The Department of Veterans Affairs has announced a research partnership with Alphabet subsidiary DeepMind that will tackle issues concerning patient deterioration during hospital care.